Combined Oral Contraceptive Use and the Risk of Cervical Cancer: Literature Review

 

 Permissions and Reprints

Abstract

Cervical cancer (CC) is caused by persistent infection of human papillomavirus of high oncogenic risk (hr-HPV); however, several cofactors are important in its carcinogenesis, such as smoking, multiparity, and prolonged use of oral hormonal contraceptives (COCs). Worldwide, 16% of women use COCs, whereas in Brazil this rate is of ∼ 30%. The safety and adverse effects of COCs are widely discussed in the literature, including the increase in carcinogenic risk. Due to the existence of several drugs, combinations, and dosages of COCs, it is hard to have uniform information in epidemiological studies. Our objective was to perform a narrative review on the role of COCs use in the carcinogenesis of cervical cancer. Several populational studies have suggested an increase in the incidence of cervical cancer for those who have used COCs for > 5 years, but other available studies reach controversial and contradictory results regarding the action of COCs in the development of CC.

Resumo

O câncer cervical (CC) é causado pela infecção persistente pelo papilomavírus humano de alto risco oncogênico (hr-HPV); entretanto, vários cofatores são importantes na sua carcinogênese, como tabagismo, multiparidade e uso prolongado de contraceptivos hormonais orais (COCs). No mundo, 16% das mulheres usam AOCs, enquanto no Brasil essa taxa é de ∼ 30%. A segurança e os efeitos adversos dos COCs são amplamente discutidos na literatura, incluindo o aumento do risco carcinogênico. Devido à existência de várias drogas, combinações e dosagens de COCs, é difícil ter informações uniformes em estudos epidemiológicos. Nosso objetivo foi realizar uma revisão narrativa sobre o papel do uso de COCs na carcinogênese do câncer cervical. Vários estudos populacionais têm sugerido aumento da incidência de câncer de colo uterino para aquelas que usam COCs há mais de 5 anos, mas outros estudos disponíveis chegam a resultados controversos e contraditórios quanto à ação dos COCs no desenvolvimento do CCU.

Publication History

Received: 17 March 2023

Accepted: 14 August 2023

Article published online:
23 December 2023

© 2023. Federação Brasileira de Ginecologia e Obstetrícia. This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/)

Thieme Revinter Publicações Ltda.
Rua do Matoso 170, Rio de Janeiro, RJ, CEP 20270-135, Brazil

• References

• 1 Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin 2023; 73 (01) 17-48
  CrossrefPubMedGoogle Scholar
• 2 Estimativa 2023 : incidência de câncer no Brasil. Vigilância CdPe, editor. Rio de Janeiro: INCA; 2022: 160
  Google Scholar
• 3 Castellsagué X. Natural history and epidemiology of HPV infection and cervical cancer. Gynecol Oncol 2008; 110 (3, Suppl 2) S4-S7
  CrossrefPubMedGoogle Scholar
• 4 Muñoz N, Franceschi S, Bosetti C, Moreno V, Herrero R, Smith JS. et al; International Agency for Research on Cancer. Multicentric Cervical Cancer Study Group. Role of parity and human papillomavirus in cervical cancer: the IARC multicentric case-control study. Lancet 2002; 359 (9312): 1093-1101
  CrossrefPubMedGoogle Scholar
• 5 Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV. et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999; 189 (01) 12-19
  CrossrefPubMedGoogle Scholar
• 6 Doorbar J, Quint W, Banks L, Bravo IG, Stoler M, Broker TR. et al. The biology and life-cycle of human papillomaviruses. Vaccine 2012; 30 (Suppl. 05) F55-F70
  CrossrefPubMedGoogle Scholar
• 7 Castle PE, Walker JL, Schiffman M, Wheeler CM. Hormonal contraceptive use, pregnancy and parity, and the risk of cervical intraepithelial neoplasia 3 among oncogenic HPV DNA-positive women with equivocal or mildly abnormal cytology. Int J Cancer 2005; 117 (06) 1007-1012
  CrossrefPubMedGoogle Scholar
• 8 Rana MJ, Goli S. Tracing long-term trajectories of contraceptive practice across 185 countries. PLoS One 2018; 13 (10) e0205927
  CrossrefPubMedGoogle Scholar
• 9 Sedgh G, Singh S, Hussain R. Intended and unintended pregnancies worldwide in 2012 and recent trends. Stud Fam Plann 2014; 45 (03) 301-314
  CrossrefPubMedGoogle Scholar
• 10 Contraceptive use by method 2019 : data booklet. New York: New York; 2019. 25 p.
  PubMed
• 11 Prentice RL, Thomas DB. On the epidemiology of oral contraceptives and disease. Adv Cancer Res 1987; 49: 285-401
  CrossrefPubMedGoogle Scholar
• 12 Williams RS. Benefits and risks of oral contraceptive use. Postgrad Med 1992; 92 (07) 155-157 161–162, 168–171
  CrossrefPubMedGoogle Scholar
• 13 Dragoman MV. The combined oral contraceptive pill – recent developments, risks and benefits. Best Pract Res Clin Obstet Gynaecol 2014; 28 (06) 825-834
  CrossrefPubMedGoogle Scholar
• 14 Swan SH, Petitti DB. A review of problems of bias and confounding in epidemiologic studies of cervical neoplasia and oral contraceptive use. Am J Epidemiol 1982; 115 (01) 10-18
  CrossrefPubMedGoogle Scholar
• 15 Petitti DB, Porterfield D. Worldwide variations in the lifetime probability of reproductive cancer in women: implications of best-case, worst-case, and likely-case assumptions about the effect of oral contraceptive use. Contraception 1992; 45 (02) 93-104
  CrossrefPubMedGoogle Scholar
• 16 Sperling MA. Complications of systemic oral contraceptive therapy: Neoplasm–breast, uterus, cervix and vagina. West J Med 1975; 122 (01) 42-49
  PubMedGoogle Scholar
• 17 Thomas DB. Role of exogenous female hormones in altering the risk of benign and malignant neoplasms in humans. Cancer Res 1978; 38 (11 Pt 2): 3991-4000
  PubMedGoogle Scholar
• 18 La Vecchia C, Tavani A, Franceschi S, Parazzini F. Oral contraceptives and cancer. A review of the evidence. Drug Saf 1996; 14 (04) 260-272
  CrossrefPubMedGoogle Scholar
• 19 Khoo SK. Cancer risks and the contraceptive pill. What is the evidence after nearly 25 years of use?. Med J Aust 1986; 144 (04) 185-190
  CrossrefPubMedGoogle Scholar
• 20 IARC monographs on the evaluation of the carcinogenic risk of chemicals to humans. Sex hormones (II). IARC Monogr Eval Carcinog Risk Chem Hum 1979; 21: 11-561
  PubMedGoogle Scholar
• 21 Humans IWGotEoCRt. Pharmaceuticals. IARC Monogr Eval Carcinog Risks Hum 2012; 100 (Pt A): 1-401
  PubMedGoogle Scholar
• 22 Gierisch JM, Coeytaux RR, Urrutia RP, Havrilesky LJ, Moorman PG, Lowery WJ. et al. Oral contraceptive use and risk of breast, cervical, colorectal, and endometrial cancers: a systematic review. Cancer Epidemiol Biomarkers Prev 2013; 22 (11) 1931-1943
  CrossrefPubMedGoogle Scholar
• 23 Kamani M, Akgor U, Gültekin M. Review of the literature on combined oral contraceptives and cancer. Ecancermedicalscience 2022; 16: 1416
  CrossrefPubMedGoogle Scholar
• 24 Schlesselman JJ. Net effect of oral contraceptive use on the risk of cancer in women in the United States. Obstet Gynecol 1995; 85 (5 Pt 1): 793-801
  CrossrefPubMedGoogle Scholar
• 25 Arbeit JM, Howley PM, Hanahan D. Chronic estrogen-induced cervical and vaginal squamous carcinogenesis in human papillomavirus type 16 transgenic mice. Proc Natl Acad Sci U S A 1996; 93 (07) 2930-2935
  CrossrefPubMedGoogle Scholar
• 26 Brake T, Lambert PF. Estrogen contributes to the onset, persistence, and malignant progression of cervical cancer in a human papillomavirus-transgenic mouse model. Proc Natl Acad Sci U S A 2005; 102 (07) 2490-2495
  CrossrefPubMedGoogle Scholar
• 27 Chung SH, Wiedmeyer K, Shai A, Korach KS, Lambert PF. Requirement for estrogen receptor alpha in a mouse model for human papillomavirus-associated cervical cancer. Cancer Res 2008; 68 (23) 9928-9934
  CrossrefPubMedGoogle Scholar
• 28 Oral contraceptives, combined. IARC Monogr Eval Carcinog Risks Hum 1999; 72: 49-338
  PubMedGoogle Scholar
• 29 Moodley M, Moodley J, Chetty R, Herrington CS. The role of steroid contraceptive hormones in the pathogenesis of invasive cervical cancer: a review. Int J Gynecol Cancer 2003; 13 (02) 103-110
  CrossrefPubMedGoogle Scholar
• 30 Negrini BP, Schiffman MH, Kurman RJ, Barnes W, Lannom L, Malley K. et al. Oral contraceptive use, human papillomavirus infection, and risk of early cytological abnormalities of the cervix. Cancer Res 1990; 50 (15) 4670-4675
  PubMedGoogle Scholar
• 31 Hildesheim A, Reeves WC, Brinton LA, Lavery C, Brenes M, De La Guardia ME. et al. Association of oral contraceptive use and human papillomaviruses in invasive cervical cancers. Int J Cancer 1990; 45 (05) 860-864
  CrossrefPubMedGoogle Scholar
• 32 Kjellberg L, Hallmans G, Ahren AM, Johansson R, Bergman F, Wadell G. et al. Smoking, diet, pregnancy and oral contraceptive use as risk factors for cervical intra-epithelial neoplasia in relation to human papillomavirus infection. Br J Cancer 2000; 82 (07) 1332-1338
  CrossrefPubMedGoogle Scholar
• 33 Smith JS, Green J, Berrington de Gonzalez A, Appleby P, Peto J, Plummer M. et al. Cervical cancer and use of hormonal contraceptives: a systematic review. Lancet 2003; 361 (9364): 1159-1167
  CrossrefPubMedGoogle Scholar
• 34 Anastasiou E, McCarthy KJ, Gollub EL, Ralph L, van de Wijgert JHHM, Jones HE. The relationship between hormonal contraception and cervical dysplasia/cancer controlling for human papillomavirus infection: A systematic review. Contraception 2022; 107: 1-9
  CrossrefPubMedGoogle Scholar
• 35 Vessey MP, Lawless M, McPherson K, Yeates D. Neoplasia of the cervix uteri and contraception: a possible adverse effect of the pill. Lancet 1983; 2 (8356): 930-934
  CrossrefPubMedGoogle Scholar
• 36 Wright NH, Vessey MP, Kenward B, McPherson K, Doll R. Neoplasia and dysplasia of the cervix uteri and contraception: a possible protective effect of the diaphragm. Br J Cancer 1978; 38 (02) 273-279
  CrossrefPubMedGoogle Scholar
• 37 Swan SH, Brown WL. Vasectomy and cancer of the cervix. N Engl J Med 1979; 301 (01) 46
  CrossrefPubMedGoogle Scholar
• 38 Moreno V, Bosch FX, Muñoz N, Meijer CJLM, Shah KV, Walboomers JMM. et al; International Agency for Research on Cancer. Multicentric Cervical Cancer Study Group. Effect of oral contraceptives on risk of cervical cancer in women with human papillomavirus infection: the IARC multicentric case-control study. Lancet 2002; 359 (9312): 1085-1092
  CrossrefPubMedGoogle Scholar
• 39 Moodley J. Combined oral contraceptives and cervical cancer. Curr Opin Obstet Gynecol 2004; 16 (01) 27-29
  CrossrefPubMedGoogle Scholar
• 40 IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. Combined estrogen-progestogen contraceptives and combined estrogen-progestogen menopausal therapy. IARC Monogr Eval Carcinog Risks Hum 2007; 91: 1-528
  PubMedGoogle Scholar
• 41 Appleby P, Beral V, Berrington de González A, Colin D, Fransceschi S, Goodhill A. et al; International Collaboration of Epidemiological Studies of Cervical Cancer. Cervical cancer and hormonal contraceptives: collaborative reanalysis of individual data for 16,573 women with cervical cancer and 35,509 women without cervical cancer from 24 epidemiological studies. Lancet 2007; 370 (9599): 1609-1621
  CrossrefPubMedGoogle Scholar
• 42 Invasive cervical cancer and combined oral contraceptives. WHO collaborative study of neoplasia and steroid contraceptives. Br Med J (Clin Res Ed) 1985; 290 (6473): 961-965
  CrossrefPubMedGoogle Scholar
• 43 WHO Collaborative Study of Neoplasia and Steroid Contraceptives. Invasive squamous-cell cervical carcinoma and combined oral contraceptives: results from a multinational study. Int J Cancer 1993; 55 (02) 228-236
  CrossrefPubMedGoogle Scholar
• 44 Roura E, Travier N, Waterboer T, Sanjosé S, Bosch FX, Pawlita M. et al. The Influence of Hormonal Factors on the Risk of Developing Cervical Cancer and Pre-Cancer: Results from the EPIC Cohort. PLoS One 2016; 11 (01) e0147029
  CrossrefPubMedGoogle Scholar
• 45 Castellsagué X, Díaz M, de Sanjosé S, Muñoz N, Herrero R, Fransceschi S. et al; International Agency for Research on Cancer Multicenter Cervical Cancer Study Group. Worldwide human papillomavirus etiology of cervical adenocarcinoma and its cofactors: implications for screening and prevention. J Natl Cancer Inst 2006; 98 (05) 303-315
  CrossrefPubMedGoogle Scholar
• 46 Asthana S, Busa V, Labani S. Oral contraceptives use and risk of cervical cancer-A systematic review & meta-analysis. Eur J Obstet Gynecol Reprod Biol 2020; 247: 163-175
  CrossrefPubMedGoogle Scholar
• 47 Beral V, Hermon C, Kay C, Hannaford P, Darby S, Reeves G. Mortality associated with oral contraceptive use: 25 year follow up of cohort of 46 000 women from Royal College of General Practitioners' oral contraception study. BMJ 1999; 318 (7176): 96-100
  CrossrefPubMedGoogle Scholar
• 48 Syrjänen K, Shabalova I, Petrovichev N, Kozachenko V, Zakharova T, Pajanidi J. et al. Oral contraceptives are not an independent risk factor for cervical intraepithelial neoplasia or high-risk human papillomavirus infections. Anticancer Res 2006; 26 (6C): 4729-4740
  PubMedGoogle Scholar
• 49 Longatto-Filho A, Hammes LS, Sarian LO, Roteli-Martins C, Derchain SFM, Eržen M. et al. Hormonal contraceptives and the length of their use are not independent risk factors for high-risk HPV infections or high-grade CIN. Gynecol Obstet Invest 2011; 71 (02) 93-103
  CrossrefPubMedGoogle Scholar
• 50 Peng Y, Wang X, Feng H, Yan G. Is oral contraceptive use associated with an increased risk of cervical cancer? An evidence-based meta-analysis. J Obstet Gynaecol Res 2017; 43 (05) 913-922
  CrossrefPubMedGoogle Scholar
• 51 Iversen L, Sivasubramaniam S, Lee AJ, Fielding S, Hannaford PC. Lifetime cancer risk and combined oral contraceptives: the Royal College of General Practitioners' Oral Contraception Study. Am J Obstet Gynecol 2017; 216 (06) 580.e1-580.e9
  CrossrefPubMedGoogle Scholar